Related Experiment Video

Updated: Aug 19, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Gastrin levels in patients with migraine and cluster headache

A Klimek

    European Neurology
    |January 1, 1982
    PubMed

    More Related Videos

    Investigating Migraine-Like Behavior Using Light Aversion in Mice05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache05:40

    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

    Published on: July 29, 2021

    Related Concept Videos

    Cholinergic Receptors: Muscarinic01:25

    Cholinergic Receptors: Muscarinic

    The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
    The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
    Cholinergic Antagonists: Therapeutic Uses01:26

    Cholinergic Antagonists: Therapeutic Uses

    Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
    Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
    Gastritis-II: Pathophysiology01:17

    Gastritis-II: Pathophysiology

    Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
    In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
    In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
    Gastritis can stem from various causes, each...
    Peptic Ulcer Disease IV: Management01:26

    Peptic Ulcer Disease IV: Management

    Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
    The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
    Pharmacological management
    The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
    Gastritis II: Pathophysiology01:26

    Gastritis II: Pathophysiology

    The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
    Pyloric Obstruction01:11

    Pyloric Obstruction

    Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...